Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert L Coffman

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Nature Immunology|May 23, 2006
Origins of the T(H)1-T(H)2 model: a personal perspectiveRobert L Coffman
Immunological Reviews|July 11, 2008
Development of TLR inhibitors for the treatment of autoimmune diseasesFranck J Barrat, Robert L Coffman
The Journal of Experimental Medicine|June 22, 2005
Nonhuman primate models of asthmaRobert L Coffman, Edith M Hessel
Vaccine|March 12, 2026
A narrative review of immune-mediated adverse events in clinical trials of CpG oligonucleotide toll-like receptor 9 agonistsRobert S Janssen, Robert L Coffman
Methods in Molecular Biology (Clifton, N.J.)|April 21, 2009
Biomarkers measuring the activity of Toll-like receptor ligands in clinical development programsPaul Sims, Robert L Coffman, Edith M Hessel
Immunity|October 30, 2010
Vaccine adjuvants: putting innate immunity to workRobert L Coffman, Alan Sher, Robert A Seder
Science Translational Medicine|July 29, 2011
Assessing the safety of adjuvanted vaccinesS Sohail Ahmed, Stanley A Plotkin, Steven Black, et al.
Immunity|September 27, 2006
Toll-like receptor recognition regulates immunodominance in an antimicrobial CD4+ T cell responseFelix Yarovinsky, Holger Kanzler, Sara Hieny, et al.
Nature Medicine|May 5, 2007
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonistsHolger Kanzler, Franck J Barrat, Edith M Hessel, et al.
European Journal of Immunology|November 24, 2007
Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptomsFranck J Barrat, Thea Meeker, Jean H Chan, et al.
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Nature Immunology|May 23, 2006
Origins of the T(H)1-T(H)2 model: a personal perspectiveRobert L Coffman
Immunological Reviews|July 11, 2008
Development of TLR inhibitors for the treatment of autoimmune diseasesFranck J Barrat, Robert L Coffman
The Journal of Experimental Medicine|June 22, 2005
Nonhuman primate models of asthmaRobert L Coffman, Edith M Hessel
Vaccine|March 12, 2026
A narrative review of immune-mediated adverse events in clinical trials of CpG oligonucleotide toll-like receptor 9 agonistsRobert S Janssen, Robert L Coffman
Methods in Molecular Biology (Clifton, N.J.)|April 21, 2009
Biomarkers measuring the activity of Toll-like receptor ligands in clinical development programsPaul Sims, Robert L Coffman, Edith M Hessel
Immunity|October 30, 2010
Vaccine adjuvants: putting innate immunity to workRobert L Coffman, Alan Sher, Robert A Seder
Science Translational Medicine|July 29, 2011
Assessing the safety of adjuvanted vaccinesS Sohail Ahmed, Stanley A Plotkin, Steven Black, et al.
Immunity|September 27, 2006
Toll-like receptor recognition regulates immunodominance in an antimicrobial CD4+ T cell responseFelix Yarovinsky, Holger Kanzler, Sara Hieny, et al.
Nature Medicine|May 5, 2007
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonistsHolger Kanzler, Franck J Barrat, Edith M Hessel, et al.
European Journal of Immunology|November 24, 2007
Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptomsFranck J Barrat, Thea Meeker, Jean H Chan, et al.
Pageof 7